Altay Therapeutics is a preclinical stage company, developing novel oral small molecule therapeutics for facioscapulohumeral muscular dystrophy (FSHD). The Company’s lead compound, DX5057, is designed to address the underlying genetic driver of the disease, offering a convenient oral treatment option for a disease affecting approximately 800,000 people worldwide, the third most common inherited muscular dystrophy, for which no disease-modifying therapy is currently approved.

Sound Contact: Ester Sklarsky (Board Director)

Read an interview with CEO, Dr. Jim Breitmeyer, M.D., Ph.D: Eagerly advancing beyond ‘undruggable’ to create novel therapies

From a laboratory breakthrough to New York Times Square!

2026.10.222026.10.22 / We are incredibly thrilled to see our recent Series A funding milestone lit up on one of the world’s most iconic stages. Seeing our startup’s name in the heart of NYC is a powerful reminder of how fa …

Eagerly advancing beyond ‘undruggable’ to create novel therapies

2026.10.152026.10.16 / Altay Therapeutics is racing into the clinical stage trials of its first small-molecule inhibitor targeting transcription factors, something many pharmaceutical researchers considered nearly impossib …

Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic

2026.10.152026.10.15 / DX5057 is an orally administered small molecule designed to inhibit DUX4 transcriptional activity and expression of its targeted proteins Clinical program will explore DUX4-related biomarkers and …

Sound Contact:

Ester Sklarsky

M.Sc., Principal